Европейски съюз - български - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - Множествена миелома - Антинеопластични средства - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Европейски съюз - български - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - Множествена миелома - Антинеопластични средства - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

България - български - Изпълнителна агенция по лекарствата

om pharma s.a. - лидокаин хидрохлорид, монохидрат довязывать калций, дексаметазон ацетат -

България - български - БАБХ (Българска агенция по безопасност на храните)

vétoquinol sa - clotrimasolum, Марбофлоксацин, Дексаметазона ацетат - капки за уши, суспензия - 10 mg/ml, 3 mg/ml, 0.9 mg/ml - кучета

България - български - БАБХ (Българска агенция по безопасност на храните)

veyx-pharma gmbh - Преднизолона ацетат, Дексаметазон - инжекционна суспензия - 7.50 mg/ml; 2.50 mg/ml - коне, котки, кучета

България - български - БАБХ (Българска агенция по безопасност на храните)

virbac s.a - Гентамицин (като сулфат гентамицина), thiabendazole, dexamethazone (като dexamethazone ацетат) - капки за уши, суспензия - 3 mg/g; 40 mg/g, 0,903 mg/g - котки, кучета

Европейски съюз - български - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - Множествена миелома - Антинеопластични средства - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.